Lisanne A H Bevers

5PUBLICATIONS
0CO-AUTHORS
Infant and child healthNutritional epidemiologyAdolescent health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 29, 2026
Simulation-Based Predictions to Support the Development of a Pediatric Fixed-Dose Combination of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumarate.

|Jul 17, 2025
The Effects on the Growth of HIV-exposed Uninfected Infants of Initiating Dolutegravir-based Versus Efavirenz-based cART in Late Pregnancy (DolPHIN-2).

Lisa Hagens, Lisanne A H Bevers, Thokozile R Malaba

|May 02, 2024
Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers.

Lisanne A H Bevers, Anne E M Kamphuis, L C Wendy van der Wekken-Pas

|Apr 04, 2024
Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers.

Lisanne A H Bevers, Anne E M Kamphuis, L C Wendy van der Wekken-Pas

|Jun 06, 2023
Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial.

Lisanne A H Bevers, Hylke Waalewijn, Alexander J Szubert

Pageof 1

Frequent Collaborators